Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $8
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.
Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $10 to $8.